DNA sequence specificity for topoisomerase II poisoning by the quinoxaline anticancer drugs XK469 and CQS

Molecular Pharmacology

Volumn 63, Issue 6, 2003, Pages 1382-1388

  Gao, Hanlin ^a,c   Yamasaki, Edith F ^a   Chan, Kenneth K ^a   Shen, Linus L ^b   Snapka, Robert M ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b ABBOTT LABORATORIES   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (7 CHLOROQUINOXALINYLOXY)PHENOXY]PROPIONIC ACID; 2,3 BIS(3,5 DIOXO 1 PIPERAZINYL)BUTANE; 5 CHLOROSULFAQUINOXALINE; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; MITOXANTRONE; NSC 697887; QUINOXALINE DERIVATIVE; TENIPOSIDE; UNCLASSIFIED DRUG; XK 469;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DNA CLEAVAGE; DNA SEQUENCE; DRUG BINDING SITE; ENZYME BINDING; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN DNA BINDING;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; DNA; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MOLECULAR SEQUENCE DATA; QUINOXALINES; SULFANILAMIDES; TENIPOSIDE;

EID: 0038102249     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.63.6.1382     Document Type: Article

References (33)

1. Austin CA, Marsh KL, Wasserman RA, Willmore E, Sayer PJ, Wang JC, and Fisher LM (1995) Expression, domain structure and enzymatic properties of an active recombinant human DNA topoisomerase IIb. J Biol Chem 270:15739-15746.
2. Borgnetto ME, Tinelli S, Carminati L, and Capranico G (1999) Genomic sites of topoisomerase II activity determined by comparing DNA breakage enhanced by three distinct poisons. J Mol Biol 285:545-554.
3. Capranico G, Binaschi M, Borgnetto ME, Zunino F, and Palumbo M (1997) A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons. Trends Pharmacol Sci 18:323-329.
4. Capranico G, De Isabella P, Tinelli S, Bigioni M, and Zunino F (1993) Similar sequence specificity of mitoxantrone and VM-26 stimulation of in vitro DNA cleavage by mammalian DNA topoisomerase II. Biochemistry 32:3038-3046.
5. Capranico G, Guano F, Moro S, Zagotto G, Sissi C, Gatto B, Zunino F, Menta E, and Palumbo M (1998) Mapping drug interactions at the covalent topoisomerase II-DNA complex by bisantrene/amsacrine congeners. J Biol Chem 273:12732-12739.
6. Capranico G, Palumbo M, Tinelli S, Mabilia M, Pozzan A, and Zunino F (1994a) Conformational drug determinants of the sequence specificity of drug-stimulated topoisomerase II DNA cleavage. J Mol Biol 235:1218-1230.
7. Capranico G, Palumbo M, Tinelli S, and Zunino F (1994b) Unique sequence specificity of topoisomerase II DNA cleavage stimulation and DNA binding mode of streptonigrin. J Biol Chem 269:25004-25009.
8. Capranico G, Zunino F, Kohn KW, and Pommier Y (1990) Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity. Biochemistry 29:562-569.
9. Catapano CV, Carbone GMR, Pisani F, Qiu J, and Fernandes DJ (1997) Arrest of replication fork progression at sites of topoisomerase II-mediated DNA cleavage in human leukemia CEM cells incubated with VM-26. Biochemistry 36:5739-5748.
10. Chen AY and Liu LF (1994) DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 34:191-218.
11. Corbett TH, LoRusso P, Demchick L, Simpson C, Pugh S, White K, Kushner J, Polin L, Meyer J, Czarnecki J, et al. (1998) Preclinical antitumor efficacy of analogs of XK469: sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate. Investig New Drugs 16:129-139.
12. Cornarotti M, Tinelli S, Willmore E, Zuninio F, Fisher LM, Austin CA, and Capranico G (1996) Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIa (P170) and IIb (P180). Mol Pharmacol 50:1463-1471.
13. Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST, and Mirabelli CK (1989) Biochemical and pharmacological properties of P170 and P180 forms of topoisomerase II. Biochemistry 28:8154-8160.
14. Gao H, Yamasaki EF, Chan KK, Shen LL, and Snapka RM (2000) Chloroquinoxaline sulfonamide (NSC 339004) is a topoisomerase IIalpha/beta poison. Cancer Res 60:5937-5940.
15. Gao HL, Huang KC, Yamasaki EF, Chan KK, Chohan L, and Snapka RM (1999) XK469, a selective topoisomerase IIb poison. Proc Natl Acad Sci USA 96:12168-12173.
16. Guano F, Pourquier P, Tinelli S, Binaschi M, Bigioni M, Animati F, Manzini S, Zunino F, Kohlhagen G, Pommier Y, et al. (1999) Topoisomerase poisoning activity of novel disaccharide anthracyclines. Mol Pharmacol 56:77-84.
17. Haldane A, Finlay GJ, and Baguley BC (1993) A comparison of the effects of aphidicolin and other inhibitors on topoisomerase II-directed cytotoxic drugs. Oncol Res 5:133-138.
18. Hsiang Y-H, Lihou MG, and Liu LF (1989) Arrest of replication forks by drugstabilized topoisomerase I-DNA cleavable complexes as a mechanism ofcell killing by camptothecin. Cancer Res 49:5077-5082.
19. Huang KC, Gao H, Yamasaki EF, Grabowski DR, Liu S, Shen LL, Chan KK, Ganapathi R, and Snapka RM (2001) Topoisomerase II poisoning by ICRF-193. J Biol Chem 276:44488-44494.
20. Kingma PS, Greider CA, and Osheroff N (1997) Spontaneous DNA lesions poison human topoisomerase IIα and stimulate cleavage proximal to leukemic 11q23 chromosomal breakpoints. Biochemistry 36:5934-5939.
21. Marsh KL, Willmore E, Tinelli S, Cornarotti M, Meczes EL, Capranico G, Fisher LM, and Austin CA (1996) Amsacrine-promoted DNA cleavage site determinants for the two human DNA topoisomerase II isoforms alpha and beta. Biochem Pharmacol 52:1675-1685.
22. Palumbo M, Gatto B, Moro S, Sissi C, and Zagotto G (2002) Sequence-specific interactions of drugs interfering with the topoisomerase-DNA cleavage complex. Biochim Biophys Acta 1587:145-154.
23. Pommier Y, Capranico G, Orr A, and Kohn KW (1991) Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide. Nucleic Acids Res 19:5973-5980.
24. Pommier Y, Orr A, Kohn KW, and Riou J-F (1992) Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human C-Myc protooncogene. Cancer Res 52:3125-3130.
25. Ryan AJ, Squires S, Strutt HL, and Johnson RT (1991) Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. Nucleic Acids Res 19:3295-3300.
26. Shin C-G and Snapka RM (1990) Exposure to camptothecin breaks leading and lagging strand simian virus 40 DNA replication forks. Biochem Biophys Res Commun 168:135-140.
27. Shoemaker RH (1986) New approaches to anticancer drug screening: the human tumor colony-forming assay. Cancer Treat Rep 70:9-12.
28. Snapka RM (1986) Topoisomerase inhibitors can selectively interfere with different stages of simian virus 40 DNA replication. Mol Cell Biol 6:4221-4227.
29. Snapka RM, Gao H, Grabowski DR, Brill D, Chan KK, Li L, Li GC, and Ganapathi R (2001) Cytotoxic mechanism of XK469: resistance of topoisomerase IIbeta knockout cells and inhibition of topoisomerase I. Biochem Biophys Res Commun 280: 1155-1160.
30. Spitzner JR, Chung IK and Muller MT (1990) Eukaryotic topoisomerase II preferentially cleaves alternating purine-pyrimidine repeats. Nucleic Acids Res 18:1-11.
31. Spitzner JR and Muller MT (1988) A consensus sequence for cleavage by vertebrate DNA topoisomerase II, Nucleic Acids Res 16:5533-5556.
32. Tewey KM, Chen GL, Nelson EM, and Liu LF (1984) Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 259:9182-9187.
33. Valeriote F, Corbett T, Edelstein M, and Baker L (1996) New in vitro screening model for the discovery of antileukemic anticancer agents. Clin Sci Rev 14:124-141.